The pharmaceutical developer, which has raised more than $85m from investors including Novo, Novartis and Amgen, has set the range for its initial public offering.
Ra Pharmaceuticals, a US-based rare blood disorder treatment developer backed by pharmaceutical companies Novo, Novartis and Amgen, set the terms yesterday for an initial public offering that could reach $81.2m.
Ra intends to offer 5.8 million shares on Nasdaq priced between $12 and $14. Undisclosed existing shareholders have expressed interest in buying $30m of shares in the offering.
Underwriters Credit Suisse, Jefferies, BMO Capital Markets and SunTrust Robinson Humphrey will have an option to acquire another 870,000 shares, which would…
